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R esistant hypertension is defined as elevated bloodpressure despite optimal or best-tolerated treatment
with at least three antihypertensive agents (one of which is
usually a diuretic). Compared to patients with controlled
blood pressure, patients with resistant hypertension are
50 % more likely to experience adverse cardiovascular
events over a 4-year period.1 The first management
guideline for management of resistant hypertension was
published by the American Heart Association (AHA) in
2008.2 Currently, there are several guidelines on treating
resistant hypertension.
Using data from the National Ambulatory Medical Care
Survey, Fontil et al. described trends in physician (general/
family practitioners, internists, cardiologists) use of recom-
mended medications for resistant hypertension before and
after the 2008 AHA guidelines.3 The authors found that use
of recommended medications for resistant hypertension was
low and remained low 2 years after guideline publication.
Assuming that the contribution of pseudo-resistant hyper-
tension to these results is limited (e.g., minimal white coat
hypertension), these findings are unfortunately in line with
previous studies that highlighted the limited impact of
guideline publications.4 Fontil et al. discussed the use of
treatment algorithms to encourage prescription of recom-
mended medications including the importance of feedback
to physicians regarding patterns of medication use. It is not
clear whether it will be sufficient to swiftly improve the
care of patients with resistant hypertension. Indeed, the
clinical inertia of physicians not specialized in hypertension
(an inertia due to several factors including misguided
acceptance of elevated blood pressure and underestimation
of cardiovascular disease risk)5 might remain a meaningful
barrier to changing treatment of resistant hypertension even
after the implementation of a treatment algorithm.
An alternative would be to consider a “detect and
redirect” approach. Non-specialist practitioners could be
trained and helped (including by algorithms) to detect
patients with resistant hypertension and then be guided to
redirect them to physicians (including general internists) or
to units/clinics specialized in the management of hyperten-
sion. In addition to improving the recommended medication
use, this approach could also contribute to improving the
investigation of resistant hypertension in general (e.g.,
diagnosis, secondary causes, target organ damage). Whether
this would improve outcomes is worthy of future research.
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